Literature DB >> 2128976

A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis.

A J Jones1, A M Meunier.   

Abstract

A rapid and precise turbidimetric clot lysis assay employing a microtitre plate reader and personal computer is described in detail. The use of such widely available instrumentation, the convenience and rapid throughput suggest the assay could be developed as a reference method with which to measure the potency of tissue plasminogen activator (t-PA) in conjunction with the WHO reference preparation. The method has been used to investigate molecular parameters involved in fibrinolysis. Aggregation status of the fibrin does not appear to influence the mechanism of plasminogen activation and clot lysis by plasmin. High ratios of plasminogen to fibrin resulted in a change in clot turbidity and in a change in the lysis profile of turbidity versus time. This is probably the result of plasminogen binding to fibrin and consequent restriction of the access of plasmin to its sites of cleavage in the fibrin. A simple model is proposed, and equations have been derived, for the kinetics of lysis which adequately describe the mechanism and which are confirmed by experimental data. This model results in estimates of the Km and kcat for the activation of plasminogen by t-PA during clot lysis of approximately 150 nM and 0.1 s-1, respectively, in excellent agreement with published values. The assay should therefore prove useful in quantitative evaluations of the molecular phenomena occurring during fibrinolysis. The more rapid activation of lys-plasminogen than glu-plasminogen by t-PA was confirmed. However, evidence was obtained that the lys-form binds more tightly to fibrin by the same factor. This observation suggested that the appropriate substrate in the kinetic model is fibrin-bound plasminogen.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2128976

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Dependence of Human Vascular Cell Surface Proteolysis on Expression of the Urokinase Receptor.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

2.  The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Patrick A McKee
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

3.  Carbon disulphide. III. Risk factors for coronary heart diseases in workers in the viscose industry.

Authors:  H Drexler; K Ulm; M Hubmann; R Hardt; T Göen; W Mondorf; E Lang; J Angerer; G Lehnert
Journal:  Int Arch Occup Environ Health       Date:  1995       Impact factor: 3.015

4.  Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.

Authors:  Oliver Königsbrügge; Günter Weigel; Peter Quehenberger; Ingrid Pabinger; Cihan Ay
Journal:  Clin Exp Med       Date:  2018-02-07       Impact factor: 3.984

5.  Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation.

Authors:  Yee Cheng Lau; Qinmei Xiong; Eduard Shantsila; Gregory Y H Lip; Andrew D Blann
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

6.  Development and implementation of tPA clot lysis activity assay using ACL TOP™ hemeostasis testing system in QC laboratories.

Authors:  Lichun Huang
Journal:  Biotechnol Rep (Amst)       Date:  2017-10-27

7.  Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis.

Authors:  Y C Lau; Q Xiong; P Ranjit; G Y H Lip; A D Blann
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.